GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GSK Pharmaceuticals has published its audited financial results for Q4 and full year FY2025-26. Consolidated revenue grew to Rs 3,822 crore from Rs 3,749 crore in the previous year (up 1.9%), while consolidated net profit increased significantly to Rs 1,036 crore from Rs 928 crore (up 11.7%). Standalone net profit stood at Rs 1,012 crore versus Rs 919 crore year earlier. Basic EPS on consolidated basis improved to Rs 61.15 per share from Rs 54.76 per share. The Board has recommended a final dividend of Rs 9 per equity share (face value Rs 10) for the financial year 2025-26, subject to shareholder approval. The results were reviewed by the Audit Committee and approved by the Board on May 13, 2026.
GSK Pharmaceuticals delivered strong profit growth of over 11% despite modest revenue expansion, indicating improved operational efficiency and cost management. The recommended dividend of Rs 9 per share is positive income news for shareholders. The stock appears to be performing well with earnings per share growth of approximately 12%.